Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma

被引:48
作者
Dann, EJ
Daugherty, CK
Larson, RA
机构
[1] Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL
[2] Section of Hematology/Oncology, University of Chicago Medical Center, MC2115, Chicago, IL 60637-1470
关键词
allogeneic marrow transplantation; Hodgkin's; lymphoma;
D O I
10.1038/sj.bmt.1700904
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
The relative benefit of allogeneic bone marrow transplantation (alloBMT) vs autologous BMT (autoBMT) for patients with relapsed or refractory Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) remains uncertain, Toxicity from graft-versus-host disease (GVHD) may diminish the potential benefits both of graft-versus-tumor activity and of receiving uncontaminated donor marrow stem cells, From 1987 to 1995, 27 adults (ages 18-60 years; median 36) underwent alloBMT for lymphoma after failure of standard chemotherapy, Twenty-one had NHL and sh had HD (nodular sclerosis), Thirteen patients had primary refractory disease or chemotherapy-resistant relapses; two of these had relapsed after autoBMT. Three patients had untested relapses (one of them had relapsed after autoBMT), and 11 had chemotherapy-sensitive relapses. Twenty-four received HLA-matched bone marrow from a sibling (one twin); three received haploidentical marrow cells, Nine (33%) died from lymphoma, Eleven (41%) died of treatment-related causes, Opportunistic infections were a substantial problem leading to eight of these deaths (30%). Six patients (22%) survive free of lymphoma 17-70 months post-BMT (median, 56 months); four had had sensitive relapses, one had had a resistant relapse, and one had had nontested relapse, Three have chronic GVHD (limited in one; extensive in two), One HD patient who had relapsed after autoBMT remains in remission 19 months after alloBMT. No therapy-related myelodysplasia has been observed, We conclude that alloBMT has substantial morbidity in heavily pretreated lymphoma patients due to acute toxicity, infections and GVHD. However, 22% of our KD/NHL patients have had long-term disease-free survival.
引用
收藏
页码:369 / 374
页数:6
相关论文
共 27 条
[1]   ALLOGENEIC, SYNGENEIC, AND AUTOLOGOUS MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - THE 21-YEAR SEATTLE EXPERIENCE [J].
ANDERSON, JE ;
LITZOW, MR ;
APPELBAUM, FR ;
SCHOCH, G ;
FISHER, LD ;
BUCKNER, CD ;
PETERSEN, FB ;
CRAWFORD, SW ;
PRESS, OW ;
SANDERS, JE ;
BENSINGER, WI ;
MARTIN, PJ ;
STORB, R ;
SULLIVAN, KM ;
HANSEN, JA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2342-2350
[2]   BONE-MARROW TRANSPLANTATION [J].
ARMITAGE, JO .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (12) :827-838
[3]  
ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023
[4]  
Brenner M K, 1994, J Hematother, V3, P33, DOI 10.1089/scd.1.1994.3.33
[5]   GENE-MARKING TO TRACE ORIGIN OF RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
BRENNER, MK ;
RILL, DR ;
MOEN, RC ;
KRANCE, RA ;
MIRRO, J ;
ANDERSON, WF ;
IHLE, JN .
LANCET, 1993, 341 (8837) :85-86
[6]   SEQUENTIAL NONSURGICAL AND SURGICAL STAGING OF NON-HODGKINS LYMPHOMA [J].
CHABNER, BA ;
JOHNSON, RE ;
YOUNG, RC ;
CANELLOS, GP ;
HUBBARD, SP ;
JOHNSON, SK ;
DEVITA, VT .
ANNALS OF INTERNAL MEDICINE, 1976, 85 (02) :149-154
[7]   AUTOLOGOUS VERSUS ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR NON-HODGKINS-LYMPHOMA - A CASE-CONTROLLED ANALYSIS OF THE EUROPEAN-BONE-MARROW-TRANSPLANT-GROUP REGISTRY DATA [J].
CHOPRA, R ;
GOLDSTONE, AH ;
PEARCE, R ;
PHILIP, T ;
PETERSEN, F ;
APPELBAUM, F ;
DEVOL, E ;
ERNST, P .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1690-1695
[8]  
Collett D., 1994, MODELLING SURVIVAL D, p[19, 40, 199, 53]
[9]   INCIDENCE AND CHARACTERIZATION OF SECONDARY MYELODYSPLASTIC SYNDROME AND ACUTE MYELOGENOUS LEUKEMIA FOLLOWING HIGH-DOSE CHEMORADIOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR LYMPHOID MALIGNANCIES [J].
DARRINGTON, DL ;
VOSE, JM ;
ANDERSON, JR ;
BIERMAN, PJ ;
BISHOP, MR ;
CHAN, WC ;
MORRIS, ME ;
REED, EC ;
SANGER, WG ;
TARANTOLO, SR ;
WEISENBURGER, DD ;
KESSINGER, A ;
ARMITAGE, JO .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (12) :2527-2534
[10]   HODGKINS-DISEASE - BASING TREATMENT DECISIONS ON PROGNOSTIC FACTORS [J].
FAGUET, GB .
LEUKEMIA & LYMPHOMA, 1995, 17 (3-4) :223-228